- Home
- IMCR vs VRDN Comparison
IMCR vs VRDN Comparison
Compare IMCR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VRDN
- Stock Information
- Founded
- IMCR 2008
- VRDN 2006
- Country
- IMCR United Kingdom
- VRDN United States
- Employees
- IMCR N/A
- VRDN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VRDN Medical Specialities
- Sector
- IMCR Health Care
- VRDN Health Care
- Exchange
- IMCR Nasdaq
- VRDN Nasdaq
- Market Cap
- IMCR 1.5B
- VRDN 1.2B
- IPO Year
- IMCR 2021
- VRDN N/A
- Fundamental
- Price
- IMCR $31.34
- VRDN $14.72
- Analyst Decision
- IMCR Buy
- VRDN Strong Buy
- Analyst Count
- IMCR 10
- VRDN 11
- Target Price
- IMCR $58.13
- VRDN $38.50
- AVG Volume (30 Days)
- IMCR 560.7K
- VRDN 714.5K
- Earning Date
- IMCR 08-07-2025
- VRDN 08-07-2025
- Dividend Yield
- IMCR N/A
- VRDN N/A
- EPS Growth
- IMCR N/A
- VRDN N/A
- EPS
- IMCR N/A
- VRDN N/A
- Revenue
- IMCR $333,581,000.00
- VRDN $302,000.00
- Revenue This Year
- IMCR $26.82
- VRDN N/A
- Revenue Next Year
- IMCR $8.15
- VRDN $17,102.33
- P/E Ratio
- IMCR N/A
- VRDN N/A
- Revenue Growth
- IMCR 25.75
- VRDN 4.86
- 52 Week Low
- IMCR $23.15
- VRDN $9.90
- 52 Week High
- IMCR $41.54
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- IMCR 40.28
- VRDN 52.51
- Support Level
- IMCR $35.10
- VRDN $14.31
- Resistance Level
- IMCR $37.56
- VRDN $16.05
- Average True Range (ATR)
- IMCR 1.74
- VRDN 0.81
- MACD
- IMCR -0.79
- VRDN -0.02
- Stochastic Oscillator
- IMCR 0.75
- VRDN 42.91
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).